Raw outlines from the adversarial annealing truthseeker — newest first. This is the unfiltered reasoning and source layer behind every episode.
Generated at: 2026-05-16 11:00:07 UTC - Top Stories / Major Trials - 2026 ACC.26 Late-Breaking Trials: Practice-changing data on imaging-guided PCI (reduced MACE vs angiography alone), TriClip TEER (↓ HF hospitalizations), and EMBRACE trial launch for Symplicity Spyral renal denervation in resistant HTN. - OCEAN(a)-PreEvent: Lp(a)-lowering trial recruiting; if positive, first primary-prevention event reduction data for elevated Lp(a). - Ongoing skepticism: Several small/single-center PFA adoption studies show inconsistent durability; await larger RCTs. - Guideline & Consensus Updates - 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Dyslipidemia Guideline (March 2026): Replaces 2018 cholesterol guideline; mandates lifetime Lp(a) testing, PREVENT-ASCVD equations, ApoB-selective use, CAC for risk reclassification, and LDL-C/non-HDL-C goals (lower targets for high-risk). Strong emphasis on RDN referral for hypertriglyceridemia. - 2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS CIED Lead Management Consensus (April 2026): Holistic lifelong strategy for lead extraction, new tech integration (LBBAP, single-lead DX); prioritizes patient-centered decisions over routine extraction. - Device & Procedural News - FDA approvals (April 2026): Biotronik Acticor Sky/Rivacor Sky ICD/CRT-D family with enhanced ATP, LBBAP support, and atrial sensing via single-lead DX. - Stereotaxis MAGiC magnetic ablation catheter (Jan 2026): Robotic platform completion for complex EP procedures. - PFA systems: ≥3 FDA-cleared in prior 12 months; rapid adoption but watch for long-term pulmonary vein stenosis data. - CardioMEMS: Expanded indications + Medicare coverage for broader HF monitoring. - New Drugs & Therapeutics - Enlicitide (CORALreef trial): Oral PCSK9 inhibitor met all endpoints; NDA submission underway (potential 2027 approval). - Lp(a)-targeted therapies: Multiple agents in phase 3; first outcome trials expected 2026–2027. - Imaging & Diagnostics - AI-powered voice analysis (Mayo Heart & Voice Study): Non-invasive HF monitoring in active trials. - Expanded CAC scoring: Routine use for intermediate-risk reclassification per new dyslipidemia guideline. - Practice-Changing Insights - Left bundle branch pacing (LBBP): Reduces pacing-induced cardiomyopathy vs RV pacing (April 2026 data); consider early switch in high-risk patients. - Defibrillation testing: No longer routine for S-ICDs (updated 2026 guidance). - Energy settings for AF cardioversion: Higher energies now preferred per recent evidence. - Appended: New Updates / Corrections - Correction to prior reports: Boston Scientific CONFIENT/LIVIAN approvals are from 2025 archive (not new 2026); current focus on Biotronik Sky family. - No major conflicting studies identified in searches; all high-impact trials/guidelines from peer-reviewed or society sources.
Generated at: 2026-05-15 11:00:07 UTC - Top Stories / Major Trials - CHAMPION-AF: LAAC noninferior to NOACs for stroke prevention in AF; watch for device-related complications in real-world use (NEJM 2026) - STEMI-DTU: Routine LV unloading with Impella in anterior STEMI without shock shows signal for infarct size reduction but neutral on hard outcomes; await full 1-year data before routine adoption - HI-PEITHO: Ultrasound-facilitated CDT superior to anticoagulation for intermediate-high risk PE on composite endpoint; bleeding risk remains key caveat - VESALIUS-CV: Evolocumab reduces MACE in primary prevention (no prior MI/stroke) with LDL ≥90 mg/dL; supports broader PCSK9 use but cost-effectiveness scrutiny needed - Skeptical note: Several trials (e.g., DanGer Shock follow-up) show mixed long-term signals; avoid over-extrapolation from surrogate endpoints - Guideline & Consensus Updates - 2026 ACC/AHA Multisociety Dyslipidemia Guideline (released March 2026): Replaces 2018 version; restores LDL-C goals (<55 mg/dL very high risk, <70 mg/dL high risk); emphasizes PREVENT risk equations and universal Lp(a) screening once in lifetime - Key practice shift: Earlier intensive therapy for intermediate-risk patients; RDN referral for hypertriglyceridemia emphasized - No major conflicting updates noted; aligns with recent trial data but implementation will vary by payer coverage - Device & Procedural News - TAVR long-term durability confirmed in low-risk patients (5-year Evolut Low Risk data); stable hemodynamics support expanded use - New embolic protection data for TAVI: Long-term performance reassuring but no clear mortality benefit yet - High-risk PCI unloading (CHIP-BCIS3): Percutaneous LV support feasible but outcome benefit modest in selected cohorts - Interventional caution: Complete physiology-guided revascularization favored in elderly multivessel disease (FIRE trial extension); staged approaches still reasonable in unstable patients - New Drugs & Therapeutics - Evolocumab primary prevention expansion post-VESALIUS-CV; monitor for muscle symptoms and adherence - ATTR-CM detection trial launched by AHA (cluster RCT via Get With The Guidelines-HF); addresses underdiagnosis in HFpEF elderly - No major new HF or antiplatelet agents highlighted in May 2026; focus remains on optimization of existing GDMT - Imaging & Diagnostics - Coronary vasomotor disorders in INOCA: DISCOVER INOCA registry defines prevalence; supports invasive testing in select refractory cases - Polygenic risk scores: Emerging role in risk stratification but limited additive value over PREVENT equations per recent commentary - ATTR-CM: Structured education improves diagnostic yield; echo and technetium scans remain first-line - Practice-Changing Insights - AF stroke prevention: Device vs drug trade-offs now clearer; shared decision-making essential - PE and STEMI unloading: Earlier intervention trends but patient selection critical to avoid unnecessary procedures - Lipid management: Aggressive LDL lowering feasible and beneficial; integrate Lp(a) into routine labs - Appended Updates / Corrections (New as of May 15, 2026) - Correction: Prior reports overstated STEMI-DTU mortality benefit; primary endpoint neutral on death/MI at 6 months - Update: EHRA 2026 PFA vs cryoablation trials (FACIL-AF, PERFECT-PAF) show comparable efficacy with faster procedures; no major safety signals - New: AHA cluster RCT for ATTR-CM diagnosis now recruiting; results expected 2027-2028
Generated at: 2026-05-14 11:00:07 UTC - Top Stories / Major Trials - ACC.26 Late-Breakers (March 2026, New Orleans): VESALIUS-CV (evolocumab primary prevention in high-risk no-prior-CVD patients with ASCVD or diabetes + LDL ≥90 mg/dL; NEJM simultaneous pub) showed MACE reduction—impactful for earlier PCSK9 use but note trial population excluded very high-risk; skeptical of generalizability without full subgroup data. - CHAMPION-AF: LAAC (Watchman?) vs NOAC in AF—non-inferiority on stroke/bleeding; practice shift potential but watch for device-related complications in real-world frail patients. - HI-PEITHO, STEMI DTU (Impella unloading in anterior STEMI no shock), CHIP-BCIS3 (high-risk PCI unloading): Mixed signals on mechanical support; DanGer-Shock follow-up listener feedback highlights equipoise issues in shock trials. - Lp(a) catalysts: HORIZON (pelacarsen) Phase 3 readout expected H1 2026; OCEAN(a) and ACCLAIM ongoing—high clinical relevance if positive but await hard outcomes. - Guideline & Consensus Updates - 2026 ACC/AHA/Multisociety Dyslipidemia Guideline (released March 13, 2026; JACC/Circulation): Replaces 2018; restores LDL-C goals (e.g., <70 mg/dL intermediate risk, lower for established ASCVD), PREVENT risk equations over PCEs, routine Lp(a) measurement once, emphasis on atherogenic lipoproteins and gene-editing mentions—major practice changer for lipid management and insurance coverage. - HRS/AHA expert consensus update on CIED lead management/extraction (April 2026 Heart Rhythm): Updates on extraction indications and techniques. - Skepticism note: Guidelines developed pre-VESALIUS-CV full results; future iterations likely tighten LDL targets further (<55 mg/dL for moderate atherosclerosis). - Device & Procedural News - FDA approvals: Biotronik Acticor Sky/Rivacor Sky ICD/CRT-D systems (April 2026 launch at HRS); Boston Scientific CONFIENT ICD, LIVIAN CRT-D, LATITUDE upgrades; HeartBeam 12-lead ECG synthesis software clearance for arrhythmia assessment. - TAVI: Long-term embolic protection device performance data (Cardiovascular News May 2026)—reassuring durability but no new major approvals highlighted. - Structural: Ongoing CHIP-BCIS3 and DTU unloading trials inform high-risk PCI/TAVR adjuncts. - New Drugs & Therapeutics - PCSK9 expansion via VESALIUS-CV positive primary prevention data—potential label updates. - Lp(a)-targeted: Pelacarsen (HORIZON), olpasiran, lepodisiran (ACCLAIM), muvalaplin oral (MOVE-Lp(a))—promising 80-94% reductions; outcomes trials pivotal in 2026. - Pipeline: Orforglipron (oral GLP-1), relacorilant; mavacamten adolescent oHCM Phase 3; aldosterone synthase inhibitors for resistant HTN anticipated. - Skepticism: Many early; confirm CVOTs before broad adoption, especially in elderly/frail. - Imaging & Diagnostics - ASNC: Cardiac PET with myocardial blood flow now preferred for CAD evaluation in all patients (May 2026 statement). - Digital: Apple Heart Study insights on equitable AF screening/decision tools (Nature Reviews Cardiology May 2026); HeartBeam 3D ECG for remote assessment. - Practice note: Integrate PREVENT equations and Lp(a) into risk assessment per new guidelines. - Practice-Changing Insights - Quadruple therapy timing, PFA stroke risks (Mandrola podcasts May 2026), complete vs staged revasc, polygenic scores—emphasize shared decision-making and quality metrics. - NSTEMI in frail elderly, TREAT-PVC trial insights: Caution against over-aggressive interventions without robust evidence. - Overall: ACC.26 reinforces aggressive lipid lowering and device-based AF stroke prevention; Lp(a) era approaching—monitor HORIZON closely. Appended: New Updates/Corrections - Post-ACC.26: VESALIUS-CV and CHAMPION-AF full publications available; dyslipidemia guideline already influencing LDL targets in clinics. - No major corrections identified in primary sources; ongoing monitoring for HORIZON readout and gene-editing early data.
Generated at: 2026-05-13 11:00:07 UTC Top Stories / Major Trials - HF-REVERT (ESC HF 2026, May 10): First RCT of microRNA inhibitor CDR132L post-MI with HFrEF – positive efficacy signals but early data; watch for full publication on safety/efficacy balance. - SPIRIT-HF (ACC.26): Spironolactone in HFmrEF/HFpEF – no clinical outcome benefit; reinforces skepticism on broad MRA use in preserved EF without stronger evidence. - VESALIUS-CV (NEJM/ACC.26): Evolocumab primary prevention in high-risk (atherosclerosis/diabetes, LDL ≥90 mg/dL) – MACE reduction; practice-changing for PCSK9i expansion but cost/access barriers remain. - CHAMPION-AF (NEJM/ACC.26): LAAC vs NOAC in AF – comparable stroke prevention; supports device option but device-related complications warrant careful patient selection. - SURPASS-CVOT (NEJM/ACC.26): Tirzepatide noninferior to dulaglutide in T2DM+ASCVD; modest edge but GI side effects higher – consider for dual-agonist preference. Guideline & Consensus Updates - 2026 ACC/AHA Multisociety Dyslipidemia Guideline (March 2026): Replaces 2018; adopts PREVENT risk equations, restores LDL-C goals (<55 mg/dL very high risk, <70 intermediate), recommends one-time Lp(a) measurement; emphasizes dietitian referral for hypertriglyceridemia. Skepticism note: Developed pre-VESALIUS-CV; future iterations may push even lower targets. Device & Procedural News - Abbott CardioMEMS HERO FDA clearance (March 2026): Next-gen wireless HF monitoring – improved remote titration potential; early real-world data pending. - EuroPCR 2026 preview (May 11): 166 late-breakers expected; focus on interventional advances in TR, complex PCI. - Ongoing Breakthrough Device designations: 243 cardiology (FDA data) – high volume but scrutinize pivotal trial rigor (e.g., patient-reported outcomes bias in TR devices). New Drugs & Therapeutics - CDR132L (HF-REVERT): Novel RNA therapy – promising but phase 2/3 scale needed before broad adoption. - Sotatercept (CADENCE, ACC.26): Pulmonary hypertension-HFpEF signal; monitor for confirmatory trials. - Mavacamten (SCOUT-HM): Adolescent obstructive HCM expansion – safety data critical in younger cohort. Imaging & Diagnostics - Oxford/UVA HCM risk model (JAMA, May 12): Combines cardiac MRI + blood biomarkers for improved sudden-death prediction in inherited HCM; enhances shared decision-making for ICDs. Practice-Changing Insights - Shift toward personalized risk (PREVENT + Lp(a)) and earlier aggressive LDL lowering; integrate with lifestyle first-line. - Device vs drug equipoise in AF (CHAMPION-AF) and HF monitoring – prioritize shared decisions and subgroup data. Appended: New Updates / Corrections - No major corrections identified in source data; HF-REVERT and HCM study are <72 hours old – await peer review for potential confounders. - Guideline implementation tools (e.g., JACC at-a-glance) now available; monitor AHA/ACC apps for updates post-ACC.26.
Generated at: 2026-05-12 11:00:07 UTC - Top Stories / Major Trials - 2026 Dyslipidemia Guideline (ACC/AHA multisociety, Mar 13) retires 2018 cholesterol guidelines; adopts PREVENT-ASCVD risk equations, mandates lifetime Lp(a) testing, restores LDL-C/non-HDL-C goals, expands CAC scoring—high clinical impact for risk stratification and therapy intensification. - Aficamten (Cytokinetics) meets all primary/secondary endpoints in ACACIA-HCM Phase 3 (reported May 2026); myosin inhibitor shows promise in obstructive HCM but await full peer-reviewed data for durability/safety caveats. - Ongoing Lp(a) trials (pelacarsen HORIZON, olpasiran OCEAN(a)-PreEvent) poised for 2026 readouts; potential first outcome data on Lp(a) lowering—monitor for practice change but note preliminary nature of prior Phase 2 signals. - Guideline & Consensus Updates - 2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS Expert Consensus Update on CIED Lead Management & Extraction (Apr 25, 2026); practical guidance on lead selection, extraction thresholds, lifelong safety—directly relevant for EP/implanting cardiologists. - New 2026 ACC/AHA Clinical Performance & Quality Measures for PAD (Jan 2026) emphasize evidence-based metrics. - Skepticism note: Avoid over-reliance on single-center or short-term observational data in guideline supplements; await RCT confirmation. - Device & Procedural News - FDA approvals: Biotronik Acticor/Rivacor Sky ICD/CRT-D family (Apr 23, 2026) with LBBAP and enhanced ATP; Abbott Ultreon 3.0 intravascular imaging software (FDA/CE mark, May 2026 updates); JenaValve Trilogy TAVR launch (Apr 2026). - Medtronic OmniaSecure lead expanded to LBB placement (Mar 2026); CardioMEMS HERO reader approval (smaller, improved workflow). - Multi-society AVR statement (ACC/SCAI/STS, May 2026) reaffirms Heart Team approach amid TAVR/SAVR media coverage. - New Drugs & Therapeutics - Enlicitide decanoate (Merck oral PCSK9i) positive Phase 3 CORALreef AddOn data (Mar 2026); potential statin add-on for hypercholesterolemia. - Kerendia (finerenone) UK approval for symptomatic chronic HF with LVEF ≥40% (Apr 2026); expands non-steroidal MRA role. - GLP-1 receptor agonists reinforced for CV risk reduction in obesity (2026 Lancet data); first-line per prior ACC guidance. - Caution: Many pipeline agents (e.g., gene therapies, ziltivekimab IL-6i) remain investigational with pending hard-outcome trials. - Imaging & Diagnostics - Abbott Ultreon 3.0 AI-enhanced OCT/IVUS integration cleared; improves PCI guidance and plaque characterization. - Philips Spectral CT Verida and IntraSight Plus platforms advance AI/spectral imaging for interventional use. - Wearable/AI FDA guidance (Jan 2026) clarifies regulatory status of consumer-grade sensors vs. clinical decision support. - Practice-Changing Insights - Shift to PREVENT equations + routine Lp(a) and ApoB testing will alter primary prevention thresholds and statin/ezetimibe/PCSK9 decisions. - Conduction system pacing emerging as alternative to BiV in select HF patients (UpToDate Apr 2026 summary). - Emphasis on multidisciplinary Heart Team and lifelong CIED management to reduce complications. - Skepticism: Prioritize RCTs over observational or surrogate-endpoint studies; many 2026 “innovations” (AI wearables, early Lp(a) therapies) require longer-term outcome validation before broad adoption. - Appended: New Updates & Corrections - No major corrections identified in reviewed sources; all data cross-checked against primary announcements (Heart Rhythm, JACC, FDA releases) as of May 12, 2026. Ongoing trials (HORIZON, ACACIA-HCM full results) may prompt rapid updates—recheck at next monthly synthesis.
Generated at: 2026-05-11 11:00:07 UTC - Top Stories / Major Trials - CHAMPION-AF, STEMI-DTU, HI-PEITHO (ACC.26): Potential practice shifts in AF ablation timing, LV unloading in anterior STEMI without shock, and earlier PE intervention; ChristianaCare involvement adds real-world credibility but full peer-reviewed data pending - GOFRESH: DASH-patterned groceries reduce BP in treated hypertension; scalable but diet-adherence skepticism warranted - Overall skepticism: Recent trials; monitor for subgroup inconsistencies or surrogate-endpoint over-reliance - Guideline & Consensus Updates - 2026 ACC/AHA Multisociety Dyslipidemia Guideline (replaces 2018): Emphasizes lifelong/primordial prevention, PREVENT-ASCVD equations, once-in-lifetime Lp(a) testing, lower LDL-C/non-HDL-C goals for higher-risk, expanded CAC; "lower is better for longer"; harmonizes with ESC but more complex - 2026 AHA/ACC Acute PE guideline referenced in implementation discussions - Clinical impact: Earlier screening/intervention for busy clinicians; watch for rollout challenges - Device & Procedural News - TAVR: Next-gen valves with improved durability/hemodynamics; lifetime management focus for younger patients; Edwards sales growth projected - EP/Interventional: Pulsed-field ablation (PFA) systems widely adopted post-FDA approvals; Shockwave coronary IVL catheter (twice as fast); guide-extension catheters; CMS expansion of ablation to ASCs - Emerging: Smaller wireless-charging pacemakers/ICDs; new device for refractory angina; skepticism on long-term durability data for novel valves/devices - New Drugs & Therapeutics - Mavacamten: Phase 3 positive for symptomatic obstructive HCM in adolescents - Lp(a)-lowering: Enlicitide (CORALreef) met endpoints; regulatory submission imminent - Gene therapy: AFTX-201 (BAG3) Fast Track for dilated cardiomyopathy - Pipeline caution: Limited 2026 cardio-specific novel approvals; prioritize outcome data over surrogates - Imaging & Diagnostics - AI-ECG: Superior perioperative risk prediction and structural remodeling detection vs traditional scores (e.g., >46k procedures studied) - Multimodality: New ACC advanced training statement for imagers proficient in echo/CT/MRI/nuclear; CCTA evolution highlighted - Impact: Rapid, low-cost risk stratification; AI reproducibility improving but human oversight essential - Practice-Changing Insights - Shift to cumulative exposure reduction via early lipid/BP control and lifestyle (diet, activity) - Precision via Lp(a)/ApoB biomarkers and CAC reclassification - AI integration for ECG/perioperative triage - Skepticism: Ensure new guidelines/devices/drugs have robust RCT backing before broad adoption; conflicting older vs new data on supplements (e.g., SPORT trial favors statins) Appended: New Updates/Corrections - No major corrections identified; dyslipidemia guideline is primary March 2026 release with ongoing implementation podcasts/discussions through May 2026
Generated at: 2026-05-10 11:00:07 UTC Top Stories / Major Trials - CHAMPION-AF (NEJM simultaneous publication, ACC.26): Watchman FLEX LAAC non-inferior to NOACs for stroke/CV death/systemic embolism (5.7% vs 4.8%) in 3,000 AF patients; major bleeding halved (10.9% vs 19%, HR 0.55). Net clinical benefit favors device. Skepticism note: Large trial, high procedural success (98.8%), but long-term durability and real-world anticoagulation adherence post-LAAC need monitoring; not yet superiority. - HI-PEITHO (ACC.26): Ultrasound-facilitated catheter-directed thrombolysis vs anticoagulation alone in intermediate-high-risk PE; functional and hemodynamic gains at 90 days. Practice impact: Supports earlier interventional strategy in select PE; watch for full publication and bleeding signals. - STEMI Door-to-Unload (DTU) and CHIP-BCIS3 (ACC.26/SCAI): LV unloading in anterior STEMI without shock and high-risk PCI; reduced infarct size and events in select cohorts. Skepticism: Promising but subgroup-specific; await larger confirmatory data before broad adoption. - VESALIUS-CV & Ez-PAVE (ACC.26): Evolocumab primary prevention benefit in diabetes/elevated LDL; intensive LDL lowering reduces MACE. Reinforces aggressive lipid control. Guideline & Consensus Updates - 2026 ACC/AHA/Multisociety Dyslipidemia Guideline (March 2026, replaces 2018): Reinstates LDL-C/non-HDL-C goals (lower for higher risk), Class I Lp(a) lifetime screening, PREVENT-ASCVD equations over Pooled Cohort, expanded CAC use. Strong clinical impact: Universal Lp(a) testing and goal-based monitoring now standard. Skepticism: Shifts from 2018 risk-stratification; early adoption may face payer pushback until PREVENT validated in diverse populations. - 2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS CIED Lead Management Consensus (April 2026): Updates extraction indications, new leadless/subcutaneous tech, lifelong monitoring. Emphasizes multidisciplinary approach and complication reduction. - New ACC/AHA Acute PE Guidelines (Q1 2026): Five risk strata, DOAC preference. Standardizes care post-HI-PEITHO. - 2026 ACC/AHA PAD Performance Measures: New metrics for BP, ACEi/ARB, antithrombotics, foot care, novel lipid therapies. Device & Procedural News - Philips AI real-time guidance FDA-cleared (March 2026) for complex minimally invasive valve repair. - Watchman FLEX & JenaValve Trilogy launches/approvals; multiple PFA systems gaining traction post-2025 approvals. - CardioMEMS expanded coverage; embolic protection device head-to-head (PROTECT H2H) in TAVR. - Interventional advances: IVUS/OCT-guided PCI, bifurcation strategies (DKCRUSH VIII), pre-TAVR PCI debates (PRO-TAVI). New Drugs & Therapeutics - Kerendia (finerenone) UK approval for HFpEF (LVEF ≥40%); US data maturing. - Enlicitide (oral PCSK9i) CORALreef trial positive; submission pending. - Gene-editing (CRISPR ANGPTL3) Phase 1 data; Phase 2 2026 planned. Skepticism: Early-stage; long-term off-target and durability concerns remain. - GLP-1 + lifestyle synergy confirmed; semaglutide PAD/CKD subgroup benefits. Imaging & Diagnostics - AI integration across echo, CT, cath lab (ACC.26 emphasis); practical workflow tools highlighted. - CAC scoring expanded in new dyslipidemia guidance for risk reclassification. - Lp(a) assay standardization push alongside guideline. Practice-Changing Insights - Shift to device-first or hybrid strategies in AF/PE/valve disease to reduce bleeding and improve outcomes. - Aggressive LDL goals and universal Lp(a) screening likely to increase specialist referrals and testing volume. - AI and remote monitoring (CardioMEMS) accelerating personalized care; busy cardiologists should prioritize implementation in high-risk clinics. - Skepticism reminder: Many ACC.26 trials simultaneously published but require replication in broader real-world cohorts; avoid over-extrapolation from non-inferiority endpoints. Appended: New Updates (Post-ACC.26, April–May 2026) - Full OCEANIC-STROKE asundexian results published; ongoing factor XI inhibitor scrutiny. - MiRus Siegel 8Fr TAVI trial initiation; STAR trial ongoing. - No major corrections to CHAMPION-AF or dyslipidemia guideline as of May 10, 2026. Appended: Corrections/Clarifications - HI-PEITHO primary endpoint focused on functional status rather than hard mortality; interpret accordingly for PE pathways. - Watchman FLEX data specific to FLEX platform; older devices not directly comparable.
Generated at: 2026-05-09 11:00:07 UTC - Top Stories / Major Trials - CHAMPION-AF (ACC.26): Watchman FLX LAAC non-inferior to DOACs for stroke/CV death/embolism (5.7% vs 4.8%); superior bleeding reduction (10.9% vs 19%). Caveat: higher ischemic stroke signal (3.2% vs 2.0%)—review patient bleeding vs stroke risk carefully before shifting from lifelong DOAC. - STEMI-DTU (ACC.26): Routine Impella LV unloading pre-PCI in anterior STEMI without shock showed no infarct size reduction vs standard care—do not adopt routinely; reinforces focus on rapid reperfusion. - HI-PEITHO (ACC.26): Ultrasound-facilitated CDT superior to anticoagulation alone for intermediate-high-risk PE—supports earlier intervention to prevent decompensation. - VESALIUS-CV: Evolocumab reduced MACE in primary prevention (high-risk atherosclerosis/diabetes, LDL ≥90 mg/dL)—consider for select statin-intolerant or very high-risk patients. - SURPASS-CVOT: Tirzepatide non-inferior to dulaglutide for CV outcomes in T2DM+ASCVD; GI side effects higher—weight-loss benefit may favor in obese patients. - Mixed IVUS guidance trials (ACC.26): Some showed benefit in complex PCI, others neutral or worse vs angiography—await full details; skeptical of blanket adoption. - Guideline & Consensus Updates - 2026 ACC/AHA Multisociety Dyslipidemia Guideline (March 2026): Restores LDL-C goals by risk; emphasizes Lp(a) testing (≥125 nmol/L flags elevated risk); earlier intensive therapy; specific pediatric and TG management sections. Practice impact: broader CAC/Lp(a) use for risk stratification. - 2026 AHA Heart Disease & Stroke Statistics: Updated US/global burden data—highlights rising HFpEF, disparities, and economic costs for resource planning. - Device & Procedural News - Watchman FLX data supports expanded LAAC consideration in eligible AF patients per CHAMPION-AF. - Impella in high-risk PCI/STEMI: Neutral or negative recent trials temper enthusiasm; use selectively. - Boston Scientific/J&J Impella and Ekos updates at ACC.26: Ongoing safety/efficacy refinements. - Limited new FDA device approvals highlighted; focus on post-market data for TriClip, renal denervation systems. - New Drugs & Therapeutics - Pediatric approvals: lomitapide (HoFH ages 2+), landiolol (SVT in children)—niche but useful for specialists. - Upcoming: Baxdrostat (aldosterone synthase inhibitor) for resistant HTN (FDA decision ~June 2026)—potential add-on for uncontrolled patients. - Tirzepatide CVOT data reinforces dual GIP/GLP-1 role beyond weight loss. - Imaging & Diagnostics - Increased role of Lp(a) and ApoB per new guidelines; selective CAC scoring for intermediate risk. - Physiology-guided complete revascularization trials support broader use in STEMI/multivessel disease. - No major new imaging modalities; emphasis on equitable digital tools (e.g., AF screening). - Practice-Changing Insights - Shift toward individualized AF stroke prevention (device vs DOAC) and earlier PE intervention. - Dyslipidemia: Treat to lower LDL goals; screen Lp(a) in select patients. - Cardiologist workforce shortage (2026 report: ~3,000 FTE gap)—impacts referral patterns and locums. - Skepticism note: Several trials (e.g., IVUS, unloading) show conflicting or null results; await peer-reviewed full publications before practice change. Appended: New Updates/Corrections - ACC.26 coverage ongoing (May 2026 ACC magazine); no major corrections to trial results identified. - Dyslipidemia guideline implementation tools now available via ACC.
Generated at: 2026-05-08 11:00:07 UTC - **Top Stories / Major Trials** - VESALIUS-CV (evolocumab primary prevention): 25% relative risk reduction in 3-point MACE (6.2% vs 8.0%) and 19% in 4-point MACE in high-risk patients (atherosclerosis or diabetes, no prior MI/stroke); LDL-C dropped to ~52 mg/dL; practice impact: supports earlier PCSK9i use, but watch for cost/access; no new safety signals (NEJM 2026). - CHAMPION-AF (Watchman FLX LAAC vs NOAC): Non-inferior efficacy (5.7% vs 4.8%), superior bleeding reduction (10.9% vs 19%); ischemic stroke slightly higher with device—skeptical of broad first-line shift pending longer data. - SURPASS-CVOT (tirzepatide vs dulaglutide): Non-inferior for MACE in T2DM + ASCVD (12.2% vs 13.1%); GI side effects higher; reinforces dual GIP/GLP-1 role. - ACC.26 Interventional: Mixed IVUS results—superior in DKCRUSH VIII bifurcations (TVF 6.1% vs 14.7%) but neutral/inferior in IVUS-CHIP complex PCI and OPTIMAL left main; tempers routine imaging enthusiasm—operator expertise and optimization criteria key; STEMI-DTU LV unloading neutral with more bleeding. - **Guideline & Consensus Updates** - 2026 ACC/AHA Multisociety Dyslipidemia Guideline (March 13, 2026; replaces 2018): Restores LDL-C goals (<55 mg/dL very high-risk, <70 mg/dL high-risk); routine one-time Lp(a) testing (≥125 nmol/L enhancer); PREVENT-ASCVD risk equations; apoB for residual risk; CAC for uncertain cases; ezetimibe/PCSK9i/bempedoic sequencing clarified; pitavastatin for HIV (REPRIEVE); no routine CK monitoring—major practice shift for primary prevention and Lp(a). - 2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS CIED Lead Management Consensus (April 25, 2026): Holistic lifelong strategy, extraction thresholds, patient-centered decisions; reduces complications via shared decision-making. - **Device & Procedural News** - Philips AI DeviceGuide FDA clearance (March 2026): Real-time guidance for complex transcatheter valve repair—potential to improve precision in TAVR/TEER. - Boston Scientific: WATCHMAN FLX CHAMPION-AF data; EKOS HI-PEITHO superior for intermediate-risk PE (61% event reduction, shorter stays). - New stroke-prevention devices for TAVR: Head-to-head with Sentinel (March 2026). - **New Drugs & Therapeutics** - Evolocumab expansion via VESALIUS-CV subgroup (diabetes primary prevention): HR 0.69 for MACE; aligns with guideline push for aggressive LDL lowering. - Tirzepatide CVOT confirmation: Broadens dual agonist use in ASCVD. - Bempedoic acid: CLEAR Outcomes integration for statin-intolerant; MACE benefit confirmed. - **Imaging & Diagnostics** - CAC scoring elevated in dyslipidemia guideline for borderline/intermediate risk; guides deferral or intensification. - ApoB and Lp(a) routine integration; Martin/Hopkins equations preferred for LDL estimation. - Skepticism note: IVUS trials show inconsistent benefit—prioritize lesion-specific optimization over blanket adoption. - **Practice-Changing Insights** - Dyslipidemia guideline + VESALIUS-CV: Shift toward earlier non-statin add-ons and Lp(a) screening for busy cardiologists; reduces events but requires cost-benefit discussion. - Interventional caution: Avoid over-reliance on IVUS in all complex PCI; focus on proven subsets (bifurcations). - Device approvals accelerate AI integration in procedures. - **Appended New Updates / Corrections (as of May 8, 2026)** - No major corrections published; VESALIUS-CV full results emphasize diabetes subgroup benefit (JAMA 2026); guideline implementation tools now available via ACC. - Ongoing: Watch for inclisiran CVOTs and long-term LAAC stroke data.
Generated at: 2026-05-07 11:00:07 UTC **Top Stories / Major Trials** - CHAMPION-AF (ACC.26, NEJM): WATCHMAN FLX LAAC noninferior to NOACs for 3-year CV death/stroke/systemic embolism in nonvalvular AF (5.7% vs 4.8%, p<0.001 noninferiority); superior bleeding safety (10.9% vs 19%, HR 0.55). Watch for slight excess ischemic stroke signal (3.2% vs 2.0%). - HI-PEITHO (ACC.26, NEJM): EKOS ultrasound-assisted catheter-directed thrombolysis + anticoagulation superior to anticoagulation alone for intermediate-risk PE (4.0% vs 10.3% primary endpoint at 7 days, 61% relative reduction); shorter ICU/hospital stay, no excess major bleeding. - VESALIUS-CV (ACC.26, NEJM): Evolocumab in primary prevention (elevated LDL-C, atherosclerosis/diabetes, no prior MI/stroke) reduced 3-point MACE (6.2% vs 8.0%, HR 0.75) and 4-point MACE (HR 0.81). Strongest evidence yet for PCSK9i in this population. - STEMI-DTU (ACC.26): Impella LV unloading before PCI in anterior STEMI without shock missed primary infarct-size endpoint (1% absolute reduction, not statistically significant); safe but no clear clinical win—skeptical of broad adoption pending larger data. - IVUS-CHIP/DKCRUSH VIII/OPTIMAL (ACC.26): Mixed intravascular imaging results in complex PCI; some trials showed no benefit or higher events vs angiography guidance—caution against routine use without patient selection. **Guideline & Consensus Updates** - 2026 ACC/AHA Multisociety Dyslipidemia Guideline (March 13, 2026; replaces 2018): Introduces Lp(a) measurement at least once; graded risk at ~125 nmol/L; restores LDL-C goals by risk; emphasizes exercise, diet, and cautions on supplements. Early screening and add-on testing highlighted. - 2026 HRS/AHA/APHRS/EHRA/IDSA/LAHRS/PACES/STS CIED Lead Management Consensus (April 25, 2026): Updates extraction indications, leadless tech integration, lifelong management; focuses on reducing complications with newer CIEDs. **Device & Procedural News** - FDA approvals (April 2026): Biotronik Acticor/Rivacor Sky ICD/CRT-D family with LBBAP support and advanced ATP; Stereotaxis MAGiC robotic ablation catheter for complex arrhythmias; Medtronic Mosaic Neo next-gen mitral bioprosthesis. - PFA systems: At least three gaining FDA approval in prior year; rapid adoption for AF ablation with shorter procedures. - Structural: Ongoing expansion of TEER (TRILUMINATE), EVOQUE tricuspid replacement, Tendyne TMVR; PROTECT H2H embolic protection in TAVI. **New Drugs & Therapeutics** - Tirzepatide (SURPASS-CVOT, ACC.26): Noninferior to dulaglutide for CV outcomes in T2DM+ASCVD; more GI side effects. - Finerenone: First robust HFpEF benefit (FINEARTS-HF) across EF spectrum; 16% reduction in CV death/worsening HF; low hyperkalemia hospitalization rate—potential new pillar. - Emerging: Lp(a) lowering agents in late trials (approval likely 2026-27 if outcomes confirm); enlicitide (oral PCSK9i) CORALreef positive. **Imaging & Diagnostics** - AI/voice: Mayo Heart & Voice study for remote HF monitoring; 98 AI cardiology devices FDA-cleared. - CardioMEMS: Expanded FDA clearance and Medicare coverage for broader HF use. **Practice-Changing Insights** - LAAC may shift to first-line in select AF patients (CHAMPION-AF safety edge). - Physiology/imaging-guided complete revascularization in ACS: Benefit even in high-bleeding-risk; default strategy emerging. - Conduction-system pacing (LBBAP): Lower complications and HF hospitalizations vs BiV in CRT candidates—watch for guideline inclusion. **Appended: New Updates & Corrections (as of May 7, 2026)** - No major post-ACC.26 corrections identified; VESALIUS-CV and CHAMPION-AF publications confirm primary results. Dyslipidemia guideline emphasizes avoiding nonprescription fish oil without benefit data. Ongoing trials (e.g., Lp(a) outcomes) flagged for future impact.